Congratulations to our client Coherus Oncology for appointing Georgia Erbez as Board Member.
Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a promising pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Their strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both their pipeline candidates as well as their industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents.
C1 Team: Christos Richards & Todd Aghazadeh